StockData
Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc. (ATXI) stock

ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/30
$0.43+0.00 (0.00%)

Close on Oct 16, 2026Market cap $1.42MP/E –Yield –

Avenue Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Avenue Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$2.90M. For fiscal 2025 it was -$3.08M. The highest annual figure on record is -$2.38M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.08M–
FY2024Dec 31, 2024-$11.28M–
FY2023Dec 31, 2023-$14.54M–
FY2022Dec 31, 2022-$8.04M–
FY2021Dec 31, 2021-$3.74M–
FY2020Dec 31, 2020-$5.21M–
FY2019Dec 31, 2019-$26.27M–
FY2018Dec 31, 2018-$21.82M–
FY2017Dec 31, 2017-$11.42M–
FY2016Dec 31, 2016-$2.38M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$707.00K-338.0%
Q1 FY2026Mar 31, 2026-$714.00K–
Q4 FY2025Dec 31, 2025-$752.00K–
Q3 FY2025Sep 30, 2025-$724.00K–
Q2 FY2025Jun 30, 2025$297.00K–
Q1 FY2025Mar 31, 2025-$1.91M–
Q4 FY2024Dec 31, 2024-$1.60M–
Q3 FY2024Sep 30, 2024-$3.16M–
Q2 FY2024Jun 30, 2024-$2.82M–
Q1 FY2024Mar 31, 2024-$3.71M–
Q4 FY2023Dec 31, 2023-$2.12M–
Q3 FY2023Sep 30, 2023-$2.07M–
Q2 FY2023Jun 30, 2023-$3.92M–
Q1 FY2023Mar 31, 2023-$6.43M–
Q4 FY2022Dec 31, 2022-$3.91M–
Q3 FY2022Sep 30, 2022-$663.00K–
Q2 FY2022Jun 30, 2022-$605.00K–
Q1 FY2022Mar 31, 2022-$2.86M–
Q4 FY2021Dec 31, 2021-$914.00K–
Q3 FY2021Sep 30, 2021-$872.00K–
Q2 FY2021Jun 30, 2021-$951.00K–
Q1 FY2021Mar 31, 2021-$1.00M–
Q4 FY2020Dec 31, 2020-$999.00K–
Q3 FY2020Sep 30, 2020-$1.04M–
Q2 FY2020Jun 30, 2020-$1.90M–
Q1 FY2020Mar 31, 2020-$1.27M–
Q4 FY2019Dec 31, 2019-$5.47M–
Q3 FY2019Sep 30, 2019-$2.32M–
Q2 FY2019Jun 30, 2019-$7.11M–
Q1 FY2019Mar 31, 2019-$11.36M–
Q4 FY2018Dec 31, 2018-$4.10M–
Q3 FY2018Sep 30, 2018-$2.61M–
Q2 FY2018Jun 30, 2018-$4.68M–
Q1 FY2018Mar 31, 2018-$10.43M–
Q4 FY2017Dec 31, 2017-$6.33M–
Q3 FY2017Sep 30, 2017-$2.85M–
Q4 FY2016Dec 31, 2016-$516.00K–
Q3 FY2016Sep 30, 2016-$383.00K–
Q2 FY2016Jun 30, 2016-$638.00K–

More Avenue Therapeutics figures

See a number that looks wrong?